Fubotv earnings beat by $0.10, revenue topped estimates
TScan Therapeutics, Inc. (NASDAQ:TCRX), a small-cap biotech company with a market capitalization of $81 million, held its 2025 annual meeting of stockholders on Monday. The company’s stock, currently trading at $1.43, has declined 53% year-to-date. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value model. According to a statement based on a recent SEC filing, stockholders voted on two proposals.
For the first proposal, stockholders elected Stephen Biggar, M.D., Ph.D., Gavin MacBeath, Ph.D., and Garry Nicholson as Class I directors. Each will serve a three-year term, ending at the company’s 2028 annual meeting, or until a successor is elected or they resign or are removed. The voting results for the directors were as follows:
- Stephen Biggar, M.D., Ph.D.: 31,050,072 votes for, 460,919 votes withheld, 14,313,890 broker non-votes
- Gavin MacBeath, Ph.D.: 31,204,939 votes for, 306,052 votes withheld, 14,313,890 broker non-votes
- Garry Nicholson: 25,650,072 votes for, 5,860,919 votes withheld, 14,313,890 broker non-votes
The second proposal concerned the ratification of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Stockholders ratified the selection with 45,724,929 votes for, 64,187 votes against, and 35,765 abstentions.
No other matters were brought to a vote at the annual meeting.
All information in this article is based on a press release statement and the company’s filing with the U.S. Securities and Exchange Commission.
In other recent news, Tscan Therapeutics Inc has caught the attention of H.C. Wainwright, a financial services firm, which has adjusted its price target for the company. Analyst Andrew S. Fein reduced the price target from $15.00 to $10.00 while maintaining a Buy rating. This adjustment follows promising clinical trial results for Tscan’s lead hematologic assets, TSC-100 and TSC-101. These assets are being evaluated for their potential as new standards of care in post-transplant treatments for conditions such as acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. The ongoing Phase 1 ALLOHA trial has shown low relapse rates and favorable trends in event-free survival data. Furthermore, the safety profile of the treatment remains clean, with no dose-limiting toxicities reported. TSC-101 is expected to enter a pivotal trial later this year, focusing on relapse-free survival. Despite a challenging market environment, H.C. Wainwright maintains a positive outlook on Tscan Therapeutics, as reflected in the continued Buy rating, albeit with a lower price target.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.